Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (SCYX)
NASDAQ:SCYX
SCYX Stock Chart & Stats
$0.66
-$0.06(-4.73%)
At close: 4:00 PM EST
$0.66
-$0.06(-4.73%)
Day’s Range― - ―
52-Week Range$0.57 - $1.31
Previous CloseN/A
Volume100.07K
Average Volume (3M)612.75K
Market Cap
$31.89M
Enterprise Value$21.55M
Total Cash (Recent Filing)$38.01M
Total Debt (Recent Filing)$2.28M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Apr 01, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding41,965,057
10 Day Avg. Volume689,890
30 Day Avg. Volume612,753
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.07
Price to Sales (P/S)15.67
P/FCF Ratio-2.44
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue7.35
Enterprise Value/Gross Profit7.35
Enterprise Value/Ebitda10.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageA low absolute debt load versus equity reduces near-term refinancing pressure and preserves strategic optionality. For a small biotech, manageable leverage supports continued R&D and commercialization spending without immediate debt-servicing strain, lowering execution risk over months.
Sustained High Gross MarginPersistently high gross margins imply the core product economics can support attractive unit-level profitability once sales scale. This structural margin buffer helps absorb commercial and R&D spend, improving long-term profitability prospects if revenue recovery occurs.
Niche Antifungal Franchise With Unmet-need FocusA focused specialty antifungal pipeline targets high unmet medical need and drug-resistant infections, creating durable demand and potential pricing power. Niche positioning can yield regulatory exclusivity, favorable reimbursement, and partnership interest, supporting medium-term commercial prospects.
Bears Say
Steep Revenue CollapseA dramatic revenue decline severely erodes operating scale, weakens commercial credibility, and undermines fixed-cost leverage. Restoring durable revenue growth will require successful re-commercialization or new approvals; absent that, financial recovery and sustainable profitability remain uncertain for months.
Material Negative Cash FlowLarge negative operating and free cash flows indicate ongoing cash burn that will necessitate external funding or meaningful cost reduction. This elevates dilution and financing risk, constrains investment in R&D and commercialization, and is a persistent execution challenge until cash flow turns positive.
Large Losses And Declining EquityMassive negative margins and falling equity reflect rapid deterioration in earnings quality and balance-sheet strength. Continued losses increase the probability of further capital raises, dilute shareholders, and limit the company's ability to self-fund growth initiatives absent a sustained operational turnaround.
SCYNEXIS News
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $0.56 and its highest was $1.31 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is $31.89M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Apr 01, 2026 which is in 41 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Nov 05, 2025. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.03.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Overvalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is 0.13.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 41,965,057 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went down -5.547%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in SCYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―
Ownership Overview
6.31% Insiders
13.39% Mutual Funds
6.27% Other Institutional Investors
70.09% Public Companies and
Individual Investors